GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease (NCT05686551)

🧪 Interventions in This Study

• Tominersen (DRUG)
• Placebo (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (70 Sites)

Showing the first 25 of 70 sites.

• Uab Medicine — Birmingham, Alabama
• Barrow Neurological Institute — Phoenix, Arizona
• University of California Davis Medical System — Sacramento, California
• CenExel Rocky Mountain Clinical Research, LLC — Englewood, Colorado
• Georgetown University — Washington D.C., District of Columbia
• University of Florida — Gainesville, Florida
• University of South Florida — Tampa, Florida
• Northwestern University — Chicago, Illinois
• University of Iowa Hospitals and Clinics — Iowa City, Iowa
• John Hopkins University School of Medicine — Baltimore, Maryland
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Henry Ford Hospital — Detroit, Michigan
• Dent Neurological Institute — Amherst, New York
• University of Pittsburgh — Pittsburgh, Pennsylvania
• Vanderbilt University Medical Center — Nashville, Tennessee
• The University of Texas Health Science Center at Houston — Houston, Texas
• EvergreenHealth Investigational Drug Services — Kirkland, Washington
• Inland Northwest Research — Spokane, Washington
• CINME — Buenos Aires,
• Hospital Ramos Mejía — CABA,
• INEBA — Capital Federal,
• Hospital Britanico de Buenos Aires — Ciudad Autonoma Buenos Aires,
• Monash Medical Centre — Clayton, Victoria
• Royal Melbourne Hospital — Parkville, Victoria
• Perron Institute for Neurological and Translational Science — Nedlands, Western Australia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Huntington Disease

• Neurobiological Predictors of Huntington's Disease (PREDICT-HD) — Iowa City, Iowa
• Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease — Nashville, Tennessee
• An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) — Clayton,
• Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) — Charlottesville, Virginia
• Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease — Rochester, New York

Explore by condition: All Huntington Disease clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.